




Searching News Database: C20
HSMN NewsFeed - 17 Jan 2019
Philips launches Azurion with FlexArm to set new standard for the future of image-guided procedures
Philips launches Azurion with FlexArm to set new standard for the future of image-guided procedures
HSMN NewsFeed - 28 Aug 2018
European Society of Cardiology incorporates iFR technology into updated guidelines for revascularization
European Society of Cardiology incorporates iFR technology into updated guidelines for revascularization
HSMN NewsFeed - 9 Mar 2018
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
HSMN NewsFeed - 7 Sep 2017
eNeura, Inc. Receives FDA Clearance for Use of SpringTMS(R) for Migraine Prevention
eNeura, Inc. Receives FDA Clearance for Use of SpringTMS(R) for Migraine Prevention
HSMN NewsFeed - 30 Jul 2014
invendo medical Appoints Nachum (Homi) Shamir to the Company's Board of Directors
invendo medical Appoints Nachum (Homi) Shamir to the Company's Board of Directors
HSMN NewsFeed - 24 Feb 2012
invendo medical Announces 510(k) Clearance by FDA for Advancement-Assisted Single-Use Colonoscopy System
invendo medical Announces 510(k) Clearance by FDA for Advancement-Assisted Single-Use Colonoscopy System
HSMN NewsFeed - 1 Jul 2010
Cyclacel Pharmaceuticals Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS
Cyclacel Pharmaceuticals Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS
HSMN NewsFeed - 7 Jul 2008
Xclair(R) Reported to Be Safe and Effective in Study Published in European Journal of Dermatology
Xclair(R) Reported to Be Safe and Effective in Study Published in European Journal of Dermatology
HSMN NewsFeed - 27 May 2008
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
HSMN NewsFeed - 21 Dec 2007
Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
HSMN NewsFeed - 8 Oct 2007
Cyclacel Pharmaceuticals Acquires Specialty Pharmaceutical Business Focused on the Oncology Market
Cyclacel Pharmaceuticals Acquires Specialty Pharmaceutical Business Focused on the Oncology Market
HSMN NewsFeed - 17 Apr 2007
Cyclacel Pharmaceuticals Reports Preclinical Seliciclib-Erlotinib Synergy Data at AACR
Cyclacel Pharmaceuticals Reports Preclinical Seliciclib-Erlotinib Synergy Data at AACR
HSMN NewsFeed - 13 Dec 2006
Cyclacel Submits IND of CYC116 an Aurora Kinase and VEGRF2 Inhibitor to Treat Cancer
Cyclacel Submits IND of CYC116 an Aurora Kinase and VEGRF2 Inhibitor to Treat Cancer
HSMN NewsFeed - 24 Oct 2006
Cyclacel Pharmaceuticals Names John Womelsdorf, Ph.D., Vice President, Business Development
Cyclacel Pharmaceuticals Names John Womelsdorf, Ph.D., Vice President, Business Development
Additional items found! 11

Members Archive contains
11 additional stories matching:
C20
(Password required)
C20
(Password required)